Repository logo
 
Publication

Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined bayesian network tool

dc.contributor.authorCaixinha Algarvio, Rogério
dc.contributor.authorConceição, Jaime
dc.contributor.authorRodrigues, Pedro Pereira
dc.contributor.authorRibeiro, Inês
dc.contributor.authorSilva, Renato Ferreira da
dc.date.accessioned2025-10-08T09:43:42Z
dc.date.available2025-10-08T09:43:42Z
dc.date.issued2025-07-30
dc.description.abstractBackground Pharmacovigilance is vital for monitoring adverse drug reactions (ADRs) and ensuring drug safety. Traditional methods are slow and inconsistent, but artificial intelligence (AI), through automation and advanced analytics, improves efficiency and accuracy in managing increasing data complexity. Aim To explore AI’s practical applications in pharmacovigilance, focusing on efficiency, process acceleration, and task automation. It also examines the use of an expert-defined Bayesian network for causality assessment in a Pharmacovigilance Centre, demonstrating its impact on decision-making. Method A comprehensive literature narrative review was conducted in MEDLINE (via PubMed), Scopus, and Web of Science using a set of targeted keywords, including but not limited to “pharmacovigilance”, “artificial intelligence”, “adverse drug reactions” and “drug safety”. Relevant studies were analysed without restrictions on publication year or language. The search was carried out in January 2025. Results AI has greatly improved pharmacovigilance by streamlining signal detection, surveillance, and ADR reporting automation. Techniques like data mining and automated signal detection have expedited safety signal identification, while duplicate detection has enhanced data precision in safety evaluations. AI has also refined real-world evidence analysis, deepening drug safety and efficacy insights. Predictive models now anticipate ADRs and drug-drug interactions, enabling proactive patient care. At a regional pharmacovigilance center, the implementation of an expert-defined Bayesian network has optimized causality assessment, reducing processing times from days to hours, minimizing subjectivity, and improving the reliability of drug safety evaluations. Conclusion AI holds significant promise for enhancing pharmacovigilance practices, yet its practical application remains primarily confined to academic research, with integration hindered by data quality issues, regulatory barriers, and the need for more transparent algorithms.eng
dc.identifier.doi10.1007/s11096-025-01975-3
dc.identifier.eissn2210-7711
dc.identifier.issn2210-7703
dc.identifier.urihttp://hdl.handle.net/10400.1/27801
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSpringer
dc.relation.ispartofInternational Journal of Clinical Pharmacy
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectArtificial intelligence
dc.subjectDrug-related side effects and adverse reactions
dc.subjectMachine learning data mining
dc.subjectNatural language processing
dc.subjectPharmacovigilance
dc.titleArtificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined bayesian network tooleng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage944
oaire.citation.issue4
oaire.citation.startPage932
oaire.citation.titleInternational Journal of Clinical Pharmacy
oaire.citation.volume47
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameCaixinha Algarvio
person.familyNameConceição
person.familyNameSilva
person.givenNameRogério
person.givenNameJaime
person.givenNameRenato Ferreira da
person.identifier.orcid0009-0005-8766-7450
person.identifier.orcid0000-0002-6201-3662
person.identifier.orcid0000-0001-6517-6021
relation.isAuthorOfPublicationcc82ff68-830b-41de-9a64-a280c4167439
relation.isAuthorOfPublication6a92b338-fb98-43f8-89d0-3e02662026f8
relation.isAuthorOfPublicationda13b258-6b19-452e-aff0-a6aba103f09f
relation.isAuthorOfPublication.latestForDiscovery6a92b338-fb98-43f8-89d0-3e02662026f8

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s11096-025-01975-3.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description: